Eight hours in bed with almost no deep sleep.

The Sleep and Recovery Stack is a physician supervised microdose protocol combining compounded microdose tirzepatide, NAD+, methylcobalamin (B12), magnesium glycinate, and L-Theanine. Five compounds addressing five distinct mechanisms: metabolic, circadian, methylation, GABA, and alpha wave activity. The stack is designed for people whose sleep architecture is the problem rather than their sleep hygiene. Most patients have already tried melatonin, magnesium glycinate alone, and sleep hygiene protocols without getting the deep sleep or REM improvement their tracker keeps flagging. A board certified MD or DO reviews your intake within 24 hours, and the full protocol ships from a licensed compounding pharmacy. No sedatives, no clinic visits. Compounded tirzepatide is not an FDA approved finished drug product.

GLP-1 receptors are expressed in the dorsomedial hypothalamus, which is involved in circadian biology, and in brain regions associated with sleep architecture. Published research links GLP-1 receptor activation to changes in sleep stage distribution, reduced inflammation associated with deep sleep disruption, and improved insulin sensitivity. Insulin dysregulation is a recognized contributor to fragmented sleep. Compounded microdose tirzepatide is prescribed at doses well below those used for weight loss; the role in this stack is metabolic and circadian support, not weight loss. All prescribing decisions are made by the supervising physician based on your clinical profile. Individual results will vary.

Standard sleep supplements generally address one or two pathways. Melatonin signals circadian timing. Magnesium oxide or citrate, the most common forms in OTC supplements, are poorly absorbed and may not reach the GABA receptor or cortisol mechanisms. L-Theanine in OTC products is often at subtherapeutic doses. The Sleep and Recovery Stack addresses five distinct mechanisms with pharmaceutical grade dosing and physician supervision. Compounded tirzepatide and methylcobalamin are prescription components that no OTC supplement can include. The stack is calibrated to your biology by a physician rather than assigned at a fixed manufacturer dose.

Each addresses a distinct sleep onset mechanism. Magnesium glycinate supports GABA receptor activity and may help reduce excess cortisol, two common inhibitors of sleep onset. The glycinate form crosses the blood-brain barrier more readily than oxide or citrate, which most OTC products use. L-Theanine promotes alpha wave brain activity and may counteract stress driven sympathetic arousal, addressing the racing mind pattern without causing sedation or morning grogginess. Together they target two distinct sleep onset mechanisms that single compound supplements may miss. The doses in the stack reflect published clinical research, not the subtherapeutic levels common in OTC sleep blends.

This is the audience the stack was designed for. Most patients on the protocol have a wearable showing one or more of: low deep sleep, low REM, high heart rate variability declines overnight, or extended sleep latency. Many patients report measurable changes in deep sleep duration, REM percentage, or HRV recovery within 4 to 8 weeks of starting the protocol. Trackers are not diagnostic, and individual results vary; the protocol is appropriate when the data supports what subjective experience is already telling you. Your physician evaluates whether the stack is clinically appropriate for your specific situation.

No. Z-drugs (Ambien, Lunesta) and benzodiazepines (Xanax, Klonopin, Valium) work by binding to GABA-A receptors and producing sedation; they are controlled substances with documented dependence risk, withdrawal effects, and complex relationships with sleep architecture, often suppressing REM and deep sleep despite producing sleep onset. The Sleep and Recovery Stack does not bind GABA-A receptors directly, does not produce sedation, and is not a controlled substance. The stack is not a replacement for prescribed sleep medications, and patients on benzodiazepines or Z-drugs should discuss any new protocol with their prescribing physician before making changes.

For most patients, no. Unlike sedative sleep medications, the components of the stack do not produce next-day drowsiness or cognitive impairment when used at prescribed doses. L-Theanine is selected specifically because it promotes alpha wave activity without sedation, addressing racing thoughts at night without producing morning grogginess. Magnesium glycinate is well tolerated and does not cause the lingering sedation associated with antihistamine sleep aids. A small subset of patients report mild morning fatigue during the first one to two weeks of titration, typically resolving as the dose stabilizes. If morning function declines on the protocol, your physician adjusts the dose.

Generally yes, with physician review. Most patients starting the stack are already taking melatonin and one or more magnesium supplements. The typical clinical recommendation is to discontinue OTC magnesium, since the stack includes pharmaceutical grade magnesium glycinate at appropriate dose, and either continue or taper melatonin based on individual response. Melatonin can be useful for circadian timing in shift workers and travelers but is often dosed too high in OTC products. Your physician reviews your full supplement stack at intake and recommends what stays, what tapers, and what is replaced.

The Sleep and Recovery Stack is not a treatment for sleep apnea, and patients with diagnosed obstructive sleep apnea should continue CPAP, dental device, or other prescribed treatments. GLP-1 medications have published research showing associations with sleep apnea severity improvements in patients with obesity; tirzepatide has Phase 3 data in this area. The stack may produce indirect effects through metabolic improvements, but the protocol's primary aim is sleep architecture support in patients without diagnosed apnea. Discuss your specific situation with your supervising physician.

High evening cortisol is a common contributor to difficulty falling asleep despite proper sleep hygiene, and it is the mechanism many sleep products do not address. Magnesium glycinate's role in GABA receptor signaling and cortisol regulation is documented in published research, which is why the glycinate form is central to the stack rather than the cheaper oxide or citrate forms. L-Theanine addresses cognitive arousal through alpha wave promotion. Compounded microdose tirzepatide may support reduction in systemic neuroinflammation associated with elevated nighttime cortisol. Many patients with the racing mind pattern report subjective improvement within 2 to 4 weeks. Individual results will vary.

Most patients report subjective changes in sleep onset and morning grogginess within the first one to two weeks. Measurable changes on Oura, Whoop, or similar trackers, including deep sleep duration, REM percentage, sleep latency, and overnight HRV, typically appear at 3 to 6 weeks as cortisol patterns normalize and circadian regulation improves. The full effect of compounded microdose tirzepatide on sleep architecture usually emerges between weeks 6 and 12. Tracker data should be averaged across at least 7 to 14 nights for meaningful comparison; single night readings are noisy. Individual results vary, and a small percentage of patients are non-responders, typically identified by week 6.

No. Unlike sedative sleep medications, the Sleep and Recovery Stack does not produce physical dependence, withdrawal symptoms, or rebound insomnia when discontinued. Magnesium glycinate, L-Theanine, NAD+ precursors, and B12 are not habit forming. Compounded tirzepatide is not associated with psychological dependence and can be stopped without a dependence taper. Some patients prefer to stay on the protocol long-term for sustained sleep architecture support; others use it for 3 to 6 months to reset sleep patterns and then continue with lifestyle and OTC support. The protocol is a monthly subscription with no commitment; you can pause or stop at any time.